Nisa Investment Advisors LLC Boosts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Nisa Investment Advisors LLC lifted its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 1,069.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,840 shares of the biopharmaceutical company’s stock after acquiring an additional 15,400 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Fate Therapeutics were worth $63,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. State Street Corp increased its holdings in Fate Therapeutics by 149.9% in the first quarter. State Street Corp now owns 14,830,084 shares of the biopharmaceutical company’s stock valued at $84,531,000 after buying an additional 8,894,625 shares during the last quarter. Millennium Management LLC increased its holdings in Fate Therapeutics by 347.1% in the fourth quarter. Millennium Management LLC now owns 2,864,476 shares of the biopharmaceutical company’s stock valued at $28,903,000 after buying an additional 2,223,752 shares during the last quarter. BlackRock Inc. increased its holdings in Fate Therapeutics by 18.0% in the first quarter. BlackRock Inc. now owns 11,476,243 shares of the biopharmaceutical company’s stock valued at $65,415,000 after buying an additional 1,750,019 shares during the last quarter. Bank of America Corp DE increased its holdings in Fate Therapeutics by 350.9% in the first quarter. Bank of America Corp DE now owns 2,154,529 shares of the biopharmaceutical company’s stock valued at $12,281,000 after buying an additional 1,676,652 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in Fate Therapeutics by 695.4% in the fourth quarter. Two Sigma Investments LP now owns 1,503,750 shares of the biopharmaceutical company’s stock valued at $15,173,000 after buying an additional 1,314,683 shares during the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Analyst Ratings Changes

FATE has been the subject of several research analyst reports. Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Wedbush upped their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Morgan Stanley upped their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 27th. Oppenheimer restated a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Finally, HC Wainwright restated a “neutral” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, March 19th. One analyst has rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.73.

Fate Therapeutics Stock Performance

Shares of FATE opened at $4.79 on Monday. Fate Therapeutics, Inc. has a fifty-two week low of $1.63 and a fifty-two week high of $8.83. The company has a market capitalization of $545.20 million, a price-to-earnings ratio of -2.92 and a beta of 1.66. The firm has a 50-day simple moving average of $6.92 and a 200-day simple moving average of $4.52.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. The firm had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same period in the prior year, the company posted ($0.58) earnings per share. Equities research analysts forecast that Fate Therapeutics, Inc. will post -1.94 EPS for the current year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.